Lyra Therapeutics (LYRA) Cash from Operations (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Cash from Operations of 6066000.0 in Q4 2025, up 17.59% on a QoQ basis from 7361000.0 in Q3 2025, and up 46.56% YoY from 4138792.64 in Q4 2024.
Lyra Therapeutics (LYRA) Cash from Operations (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Cash from Operations for 7 consecutive years, with 6066000.0 the latest figure, recorded in Q4 2025.
- Cash from Operations for Q4 2025 came in at 6066000.0, up 46.56% year-over-year; the trailing twelve-month figure through Dec 2025 was 28859000.0 (up 58.78% YoY), and the FY2025 annual result was 28859000.0, up 58.78% from the prior year.
- Cash from Operations for Q4 2025 stood at 6066000.0, up from 7361000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3381000.0 in Q2 2021, with the low at 22455000.0 in Q1 2024.
- A 5-year average of 11568950.0 and a median of 11324500.0 in 2021 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 145.21% in 2021 and slumped 350.52% in 2022, its largest moves.
- Lyra Therapeutics' Cash from Operations stood at 11297000.0 in 2021, then fell by 7.67% to 12164000.0 in 2022, then plunged by 56.68% to 19058000.0 in 2023, then jumped by 40.43% to 11352000.0 in 2024, then jumped by 46.56% to 6066000.0 in 2025.
- The last three Cash from Operations figures came in at 6066000.0 (Q4 2025), 7361000.0 (Q3 2025), and 6590000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -6.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.07 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | -7.36 Mn |
| Sep 30, 2025 | -7.36 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Dec 31, 2024 | -11.35 Mn |
| Dec 31, 2024 | -11.35 Mn |
| Sep 30, 2024 | -16.22 Mn |
| Sep 30, 2024 | -16.22 Mn |
| Jun 30, 2024 | -19.98 Mn |
| Jun 30, 2024 | -19.98 Mn |
| Mar 31, 2024 | -22.46 Mn |
| Mar 31, 2024 | -22.46 Mn |
| Dec 31, 2023 | -19.06 Mn |
| Dec 31, 2023 | -19.06 Mn |
| Sep 30, 2023 | -14.11 Mn |
| Sep 30, 2023 | -14.11 Mn |